Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yue Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6790-3402; OpenAlex author ID A5034254930, A5125174153. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2015: 3 papers · 2016: 1 paper · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 28

  1. LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. Last author DOI 10.1038/s41419-026-09075-4↗
  2. Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies. Last author DOI 10.1038/s41420-026-02948-9↗
  3. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  4. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02488-4↗
  5. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  6. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.medj.2023.07.010↗
  7. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Co-author DOI 10.1016/j.phrs.2022.106555↗
  8. Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072049↗
  9. Tumor mutation burden-related long non-coding RNAs is predictor for prognosis and immune response in pancreatic cancer. Co-author DOI 10.1186/s12876-022-02535-z↗
  10. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Co-author DOI 10.1038/s41392-021-00659-4↗
  11. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112689↗
  12. IL-17B/RB Activation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Metabolism and Growth. Co-author DOI 10.3390/cancers13215338↗
  13. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Co-author DOI 10.1038/s41392-020-0146-6↗
  14. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  15. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer. Co-author DOI 10.3390/ijms21062215↗
  16. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Co-author DOI 10.7150/thno.43093↗
  17. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2019.01160↗
  18. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Last author DOI 10.3390/cancers11060874↗
  19. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. First author DOI 10.7150/ijbs.32899↗
  20. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-018-2717-2↗
  21. Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-018-4973-6↗
  22. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗
  23. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Last author DOI 10.1155/2017/6012810↗
  24. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pan… Co-author DOI 10.1186/s12885-017-3186-8↗
  25. Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells. First author DOI 10.3892/ijo.2016.3512↗
  26. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis. Co-author DOI 10.1007/s11523-014-0323-z↗
  27. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pa… Co-author DOI 10.1007/s11523-015-0360-2↗
  28. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular "pseudoinflammation" contributing to an aggressiv… Co-author DOI 10.18632/oncotarget.2494↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christiane J. Bruns · 26 shared papers, 2015–2026 · strength 2.88
  2. Felix Popp · 13 shared papers, 2017–2026 · strength 1.59
  3. Qiongzhu Dong · 8 shared papers, 2019–2026 · strength 1.15
  4. Zhefang Wang · 6 shared papers, 2019–2026 · strength 0.97
  5. Alexander Quaas · 6 shared papers, 2021–2026 · strength 0.97
  6. Alexander Ioannis Damanakis · 4 shared papers, 2021–2024 · strength 0.61
  7. Jiahui Li · 5 shared papers, 2019–2021 · strength 0.52
  8. Jiangang Zhao · 4 shared papers, 2017–2026 · strength 0.50
  9. Thomas Schmidt · 3 shared papers, 2023–2024 · strength 0.48
  10. Su Ir Lyu · 3 shared papers, 2023–2024 · strength 0.48
  11. Karl Knipper · 3 shared papers, 2023–2024 · strength 0.48
  12. Feng Yang · 4 shared papers, 2019–2023 · strength 0.41
  13. Yan Zheng · 4 shared papers, 2019–2023 · strength 0.41
  14. Deliang Fu · 4 shared papers, 2019–2023 · strength 0.41
  15. Utz Settmacher · 3 shared papers, 2017–2024 · strength 0.35
  16. Beiyuan Hu · 3 shared papers, 2020–2023 · strength 0.33
  17. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  18. Bettina Rau · 2 shared papers, 2023–2024 · strength 0.29
  19. Maximilian Reichert · 1 shared paper, 2026 · strength 0.25
  20. Hana Algül · 1 shared paper, 2026 · strength 0.25
  21. Peter Čamaj · 5 shared papers, 2015–2017 · strength 0.25
  22. Philipp Lohneis · 2 shared papers, 2020–2021 · strength 0.23
  23. Thomas Knösel · 3 shared papers, 2017–2018 · strength 0.23
  24. Ioannis Pozios · 3 shared papers, 2017–2018 · strength 0.23
  25. Hendrik Seeliger · 3 shared papers, 2017–2018 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.